Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

If you sized SANA small after the May post, the thesis is tracking; consider letting winners run while watching for pullbacks ...

Weight Watchers went bankrupt in May, but now it promises it's trimmed the fat off its books and is ready to rejoin the ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. Eli Lilly and Company ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various ...

Lantheus Holdings offers a compelling bull case, with PYLARIFY and DEFINITY driving valuation and strong growth prospects.

This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly) By Adam Spatacco – Updated Jun 30, 2025 at 7:04AM ...

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

Meanwhile, Lilly is notching win after win. Eli Lilly's position in the weight management market makes its stock attractive, considering how fast this area is projected to grow in the coming years.

Eli Lilly is grabbing the lead in the fast-growing diabetes drug market. The company has also worked hard to diversify its pipeline. The stock is worth the premium. And that's before we get into ...